Minrin (Desmopressin Acetate)

Desmopressin is a synthetic analogue of vasopressin that selectively activates V2 receptors in the kidney collecting ducts. This triggers a cascade that inserts aquaporin‑2 channels into the cell membrane, increasing water reabsorption and concentrating urine, while also raising plasma von Willebrand factor and factor VIII levels.

The appropriate dose of Minrin is determined by the prescribing healthcare professional based on the individual’s condition, age, renal function and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety data for desmopressin in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their clinician.

To request Minrin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Minrin (desmopressin) is a selective V2‑receptor agonist, offering a longer duration of action and a lower risk of vasoconstriction compared with natural vasopressin. It is available as a nasal spray, which can be more convenient than injectable vasopressin for chronic management of diabetes insipidus and enuresis.

Minrin should be stored at room temperature, below 25 °C, in its original packaging. Protect the nasal spray from moisture and direct sunlight. Do not freeze the product, and keep it out of reach of children.

Minrin is administered intranasally. The prescribed number of sprays is delivered into one or both nostrils, usually at the same time each day. Patients should avoid blowing their nose immediately after dosing and follow any specific instructions provided by their healthcare professional.

The most serious adverse effects involve severe hyponatremia, which can lead to seizures, coma, or cerebral edema. Water intoxication and related neurological complications are also critical concerns. Patients should be monitored for signs of electrolyte imbalance, especially when fluid intake is high or when other antidiuretic agents are used.

Minrin is contraindicated in individuals with known hypersensitivity to desmopressin or any component of the formulation, uncontrolled hyponatremia, severe renal impairment, or chronic pulmonary disease with CO₂ retention. Caution is also advised for patients with a history of hyponatremia, heart failure, or uncontrolled hypertension.